It been a while since Anteris advised the market on internal NPV calculations. With the advances made since then there must be a reasonable reduction in risk metrics. It will be very interesting to hear there next valuation.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-2
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.20 |
Change
-0.800(5.71%) |
Mkt cap ! $279.0M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.00 | $13.11 | $947.2K | 71.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |